Free tool
Stocks near their 52-week high
We cover 54 companies trading within 5% of their own 52-week high. The median market value in the group is $14.36B. Across the group, the median move over the past trading day is 0.00%. 100% of the 54 with a 200-day average trade above it. Price change over the past year runs from +16.5% to +180.7% across the middle 80 percent of the group, with a median of +50.4%. Across the group, 2 companies currently carry a tier A volume signal.
Other lists in this group
Table
54 of 3,992 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| MRCK34.SA | Merck & Co., Inc. | $388.60B | Mega cap | +81.07% |
| 6MK.DE | Merck & Co., Inc. | $379.64B | Mega cap | +91.49% |
| MRK | Merck & Co., Inc. | $377.72B | Mega cap | +86.85% |
| AMGN34.SA | Amgen Inc. | $239.09B | Mega cap | +47.79% |
| AMGN | Amgen Inc. | $238.06B | Mega cap | +56.24% |
| AMG.DE | Amgen Inc. | $237.76B | Mega cap | +60.12% |
| TMO | Thermo Fisher Scientific Inc. | $234.31B | Mega cap | +30.17% |
| PFIZ34.SA | Pfizer Inc. | $161.53B | Large cap | +11.58% |
| BMYB34.SA | Bristol-Myers Squibb Company | $138.65B | Large cap | +40.74% |
| ARGX | argenx SE | $65.51B | Large cap | +47.90% |
| A1RG34.SA | argenx SE | $63.16B | Large cap | +36.97% |
| 0QF.DE | Moderna, Inc. | $59.07B | Large cap | +550.51% |
| TAKP34.SA | Takeda Pharmaceutical Company Limited | $57.22B | Large cap | +18.03% |
| BDX | Becton, Dickinson and Company | $51.81B | Large cap | +25.97% |
| NTRA | Natera, Inc. | $48.53B | Large cap | +107.59% |
| T1EV34.SA | Teva Pharmaceutical Industries Limited | $44.24B | Large cap | +94.70% |
| IQV | IQVIA Holdings Inc. | $43.04B | Large cap | +38.51% |
| QTS.DE | IQVIA Holdings Inc. | $43.01B | Large cap | −4.04% |
| I1LM34.SA | Illumina, Inc. | $34.10B | Large cap | +113.13% |
| ILU.DE | Illumina, Inc. | $34.08B | Large cap | +129.80% |
| ILMN | Illumina, Inc. | $33.95B | Large cap | +125.88% |
| BIIB34.SA | Biogen Inc. | $32.56B | Large cap | +47.86% |
| LH | Labcorp Holdings Inc. | $27.39B | Large cap | +21.14% |
| DGX | Quest Diagnostics Incorporated | $26.99B | Large cap | +38.12% |
| I1NC34.SA | Incyte Corporation | $25.83B | Large cap | +41.91% |
| GMAB.CO | Genmab A/S | $20.69B | Large cap | +36.19% |
| ERF.PA | Eurofins Scientific SE | $14.64B | Large cap | +15.60% |
| CRL | Charles River Laboratories International, Inc. | $14.09B | Large cap | +81.27% |
| B1MR34.SA | BioMarin Pharmaceutical Inc. | $12.54B | Large cap | +4.97% |
| HALO | Halozyme Therapeutics, Inc. | $12.41B | Large cap | +46.30% |
| T1CH34.SA | Bio-Techne Corporation | $11.51B | Large cap | +23.42% |
| BIO | Bio-Rad Laboratories, Inc. | $10.40B | Large cap | +32.71% |
| RGEN | Repligen Corporation | $10.25B | Large cap | +51.67% |
| APGE | Apogee Therapeutics, Inc. | $10.21B | Large cap | +257.11% |
| BIO-B | Bio-Rad Laboratories, Inc. | $9.77B | Mid cap | +47.78% |
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.00B | Mid cap | +179.08% |
| TXG | 10x Genomics, Inc. | $8.37B | Mid cap | +358.35% |
| RHC.AX | Ramsay Health Care Limited | $8.27B | Mid cap | +50.11% |
| HLUN-A.CO | H. Lundbeck A/S | $6.40B | Mid cap | +29.71% |
| CNTA | Centessa Pharmaceuticals plc | $6.27B | Mid cap | +143.24% |
| HAE | Haemonetics Corporation | $4.85B | Mid cap | +93.71% |
| HTFL | Heartflow, Inc. | $4.26B | Mid cap | +40.79% |
| ITGR | Integer Holdings Corporation | $4.25B | Mid cap | +15.84% |
| IDYA | IDEAYA Biosciences, Inc. | $4.01B | Mid cap | +66.32% |
| ABCL | AbCellera Biologics Inc. | $3.97B | Mid cap | +181.38% |
| CPRX | Catalyst Pharmaceuticals Inc | $3.85B | Mid cap | +55.97% |
| OGN | Organon & Co. | $3.62B | Mid cap | +50.67% |
| AVAH | Aveanna Healthcare Holdings Inc. | $2.97B | Mid cap | +73.50% |
| ATAI | AtaiBeckley Inc. | $2.74B | Mid cap | +61.71% |
| CDNA | CareDx, Inc. | $2.64B | Mid cap | +283.45% |
| BV3.DE | Bavarian Nordic A/S | $2.55B | Mid cap | +15.65% |
| RAPP | Rapport Therapeutics, Inc. | $2.52B | Mid cap | +250.70% |
| ATRC | AtriCure, Inc. | $2.45B | Mid cap | +29.14% |
| ZYME | Zymeworks Inc. | $2.10B | Mid cap | +96.28% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.